Morningstar Investor users sign in here.

Video

Hits and misses aplenty in first half 2020 - Part 2

Consumer stock Breville and listed property firm Charter Hall were among the highest gainers after delivering results, while Mayne Pharma and Seven West saw the sharpest falls.


Glenn Freeman: Peter, in terms of fair value upgrades, the top three that we saw were Breville, which was up 43%, Charter Hall up 20% and WorleyParsons was up 19%.

Peter Warnes: Those three companies are a bit diverse. Breville again, I would suspect that that was a company who had an IMR of nearly 27%. In other words, the initial market reaction was a positive 27%. I think that there's probably – one, it was a very, very good result, very strong result basically driven by offshore America and their penetration into Europe now. But it hasn't got a wide coverage in the investment community. And therefore, without the wide coverage, you can get bumps along the road, positively or negatively. But this is a very, very well managed company. There's no doubt we're off the pace on stock. I think we've got it about right now.

But the thing is, with Breville, Solly Lew is the major shareholder there or the most significant shareholder there. He knows retail backwards. He knows what products sell, et cetera, et cetera, et cetera. Worley surprised us in terms of – they're putting together that big acquisition that they made, and the synergy benefits coming out of that, again, will be a little bit higher than we anticipated. And they're still getting very, very significant new work in the energy space, which is quite interesting. The other stock…

Freeman: We got Charter Hall.

Warnes: Charter Hall, in the REIT space, it has made major inroads in terms of its funds management operation. It's a bit a second division, if you like, from Goodman. Goodman is the class act in this space about it. But it's in a different space. It's in industrial. Charter Hall is office – A1 office space, a little bit of industrial but the funds management business, it exploded basically in terms of assets under management and that was one of the reasons why it performed well and we increased our fair value because of the annuity style income stream that's going to there, very sticky.

Freeman: How did the healthcare sector perform given it's regarded as a more defensive sector?

Warnes: Overall, again, pretty well, and you would expect that. It's defensive and what have you. But the big three global players, CSL, Cochlear warned on coronavirus early and said it would impact their second half results, and the shock came back a little bit on that. But generally speaking, the results were okay. And ResMed was fine as well. So, the big three performed, you know, strongly in terms of reporting good solid results from their global operations Ramsay Health Care surprised us a little in terms of a fair bit of margin pressure in their Australian operations which shouldn't surprise and we trim them the fair value on Ramsay. Elsewhere, Ansell was a good result. Sonic Healthcare was a good result. Invacare was a very strong result and surprised on the upside.

Freeman: And just finally, just turning to some of the downgrades in our fair value, what are some of the biggest falls there?

Warnes: Well, the two that stood out and they're only smaller companies, they were bigger companies a year ago, was Seven West Media and main pharma. We know what's happening in the media space. Advertising is on the slide. Seven West are probably exposed more than others with their operations. They've got print and they've got magazines and they've got obviously Seven TV and it's been a very, very difficult road. On the other hand, Nine Entertainment who was a very, very solid result and it was one of the positive, if you like, IMRs. In terms of market reaction. So, in all sectors, it seems that there's one standout and other one you know just drops off a bit. Now, I guess in that in that television space, the big market shares, they do move around a little bit. Mayne Pharma they've been under the whip for quite a while. Their generic drug business in the U.S. is very competitive and they've just been, if you like, smacked on margin.

Freeman: All right. Well, then – our subscribers can view the full earning season insights on morningstar.com.au. Thanks very much for your time today, Peter.

Warnes: Pleasure, Glenn.

Freeman: Pleasure, Glenn. We will be back again directly.



© 2023 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This report has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or New Zealand wholesale clients of Morningstar Research Ltd, subsidiaries of Morningstar, Inc. Any general advice has been provided without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide at www.morningstar.com.au/s/fsg.pdf. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar’s full research reports are the source of any Morningstar Ratings and are available from Morningstar or your adviser. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782.

More from Morningstar

Bank results: the winners and losers
Video

Bank results: the winners and losers

Morningstar analyst Nathan Zaia explains how the banks did and what the future holds.
How to deal with financial stress
Video

How to deal with financial stress

More high-income earners are now also experiencing financial stress. We go through practical ways to reduce it
UniSuper CIO John Pearce on why the 60/40 portfolio is far from dead
Video

UniSuper CIO John Pearce on why the 60/40 portfolio is far from dead

The $130 Billion SuperFund Manager also talks about how he sees risk, his recent investments, and why history isn’t a good guide to the future.
Incitec Pivot: explosive upside ahead?
Video

Incitec Pivot: explosive upside ahead?

Morningstar analyst Mark Taylor believes imminent growth in explosives earnings could lift sentiment.
Why Morningstar see opportunities in coal stocks
Video

Why Morningstar see opportunities in coal stocks

Analyst Jon Mills explains why he’s recently increased fair value estimates for Australian coal companies.
Is the sharp fall in ResMed's share price justified?
Video

Is the sharp fall in ResMed's share price justified?

The potential for weight loss drugs to impact the sleep apnea giant has weighed on the share price, though Morningstar analyst Shane Ponraj thinks...